AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
NASDAQ: AMRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$12.80
+0.51% today
Updated 2026-04-29
Market cap
$4.08B
P/E ratio
58.18
P/S ratio
1.35x
EPS (TTM)
$0.22
Dividend yield
—
52W range
$7 – $15
Volume
1.9M
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.92B | $1.01B | $1.22B | $1.34B | $4.35B | $3.67B | $4.01B | $3.94B | $3.80B | $3.47B | $3.50B |
| Cash & equivalents | — | — | — | — | — | — | — | — | — | — | — |
| Current assets | — | $604.60M | $726.11M | $771.93M | $1.29B | $1.21B | $1.55B | $1.52B | $1.41B | $1.38B | $1.59B |
| Total liabilities | — | $1.20B | $1.39B | $1.72B | $3.46B | $3.32B | $3.65B | $3.57B | $3.59B | $3.41B | $3.55B |
| Current liabilities | — | $239.15M | $225.07M | $296.88M | $553.85M | $550.41M | $676.90M | $677.24M | $752.80M | $846.60M | $1.13B |
| Long-term debt | — | $424.60M | $813.54M | $1.36B | $2.63B | $2.61B | $2.74B | $2.68B | $2.59B | $2.43B | $2.16B |
| Shareholder equity | — | — | — | — | — | — | — | — | — | — | — |
| Retained earnings | — | $-181.97M | $-175.17M | $-382.79M | $-20.92M | $-377.88M | $-286.82M | $-276.20M | $-406.18M | $-490.18M | $-607.06M |
| Accounts receivable | — | $273.83M | $394.79M | $351.37M | $565.32M | $604.39M | $639.00M | $694.74M | $741.79M | $645.66M | $775.73M |
| Inventory | — | $234.97M | $266.16M | $284.04M | $457.22M | $381.07M | $490.65M | $489.39M | $530.74M | $581.38M | $612.45M |
| Goodwill | — | $29.82M | $28.44M | $26.44M | $426.23M | $419.50M | $522.81M | $593.02M | $598.85M | $598.63M | $597.44M |